SCHEMBL17396100

SCHEMBL17396100

O=C(N[C@@H]1CCCNC1)c1c[nH]cn1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PBK Q96KB5 11/20 0.52
MAPK1 P28482 1/20 0.48
OPRK1 P41145 1/20 0.48
HDAC4 P56524 1/20 0.45
PARP1 P09874 1/20 0.43
CHRNA1 P02708 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA4 P43681 1/20 0.42
CDK2 P24941 2/20 0.42
CCNA2 P20248 1/20 0.42
CDK2AP1 O14519 2/20 0.41
CHEK1 O14757 2/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20497247 1.00 PBK (0.52) PBKMAPK1OPRK1HDAC4PARP1
SCHEMBL3685973 0.84 ALDH1A1 (0.50)
SCHEMBL17396263 0.82 SMYD3 (0.52) HDAC4
SCHEMBL7512969 0.82 SMYD3 (0.43)
SCHEMBL30586871 0.78 PBK (0.49) PBKMAPK1OPRK1HDAC4PARP1
SCHEMBL20497245 0.77 MAPK1 (0.48) PBKMAPK1OPRK1HDAC4PARP1
SCHEMBL20497287 0.77 MAPK1 (0.48) PBKMAPK1OPRK1HDAC4PARP1
SCHEMBL3460359 0.77 SMYD3 (0.53) PBKMAPK1OPRK1CDK2CCNA2
SCHEMBL3462774 0.77 SMYD3 (0.53) PBKMAPK1OPRK1CDK2CCNA2
SCHEMBL31227157 0.77 GRM5 (0.68) PBKCDK2AP1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414750-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2019-09-17 US disclosed
US-20180265491-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2018-09-20 US disclosed
EP-3164509-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2017-05-10 EP disclosed
WO-2016004105-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. (US) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414750-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A PBK 3276/4885MAPK1 2360/4885OPRK1 3917/4885
US-20180265491-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A PBK 3276/4885MAPK1 2360/4885OPRK1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.